A number of firms have modified their ratings and price targets on shares of Spark Therapeutics (NASDAQ: ONCE) recently:

  • 8/5/2017 – Spark Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “
  • 8/3/2017 – Spark Therapeutics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $95.00 price target on the stock, up previously from $75.00.
  • 8/3/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $95.00 price target on the stock, up previously from $85.00.
  • 8/3/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $92.00 price target on the stock, up previously from $77.00.
  • 8/3/2017 – Spark Therapeutics had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
  • 8/3/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $92.00 price target on the stock, up previously from $70.00.
  • 8/2/2017 – Spark Therapeutics was upgraded by analysts at Chardan Capital from a “neutral” rating to a “buy” rating. They now have a $100.00 price target on the stock, up previously from $60.00.
  • 8/2/2017 – Spark Therapeutics had its price target raised by analysts at BMO Capital Markets from $69.00 to $89.00. They now have an “outperform” rating on the stock.
  • 7/27/2017 – Spark Therapeutics is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $87.00 price target on the stock.
  • 7/24/2017 – Spark Therapeutics had its “neutral” rating reaffirmed by analysts at Chardan Capital. They wrote, “We continue to expect ENDP shares to be range-bound in the near to medium term. Our recent analysis of ENDP’s additional unfunded mesh liability and discussion with a legal expert familiar with mass tort/product liability defense ligation supports our view ENDP will remain highly levered (in the 4s) and the company’s turnaround will take several years. While we view any of our potential settlement scenarios for the company’s additional unfunded mesh liability to be manageable, we believe continued pricing pressure in ENDP’s US generics base business, need for additional advertising and promotion spend to support Xiaflex growth and inability to grow through meaningful acquisitions leave ENDP little room for error.””
  • 7/24/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $85.00 price target on the stock.
  • 7/19/2017 – Spark Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/19/2017 – Spark Therapeutics was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “
  • 7/17/2017 – Spark Therapeutics was given a new $94.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/13/2017 – Spark Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/12/2017 – Spark Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “
  • 7/10/2017 – Spark Therapeutics is now covered by analysts at Jefferies Group LLC. They set a “buy” rating and a $85.00 price target on the stock.
  • 6/28/2017 – Spark Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
  • 6/22/2017 – Spark Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/20/2017 – Spark Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of Spark Therapeutics, Inc. (ONCE) traded up 2.709% on Monday, reaching $79.045. 343,601 shares of the company’s stock were exchanged. Spark Therapeutics, Inc. has a 12 month low of $35.07 and a 12 month high of $79.64. The company’s market capitalization is $2.45 billion. The firm’s 50 day moving average price is $63.15 and its 200-day moving average price is $58.70.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same period in the previous year, the company earned ($1.04) EPS. Spark Therapeutics’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, equities analysts anticipate that Spark Therapeutics, Inc. will post ($6.80) EPS for the current year.

In other news, CEO Jeffrey D. Marrazzo sold 28,650 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $80.01, for a total value of $2,292,286.50. Following the completion of the sale, the chief executive officer now owns 258,650 shares of the company’s stock, valued at $20,694,586.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Barge Joseph La sold 5,000 shares of the stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total value of $275,000.00. Following the completion of the sale, the general counsel now directly owns 9,567 shares of the company’s stock, valued at approximately $526,185. The disclosure for this sale can be found here. In the last ninety days, insiders sold 314,310 shares of company stock valued at $21,866,838. Insiders own 7.30% of the company’s stock.

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.